Several clinical trials are investigating agents that target myeloid cells. These include inhibitors of colony-stimulating factor 1 receptor (CSF1R), which is crucial for the survival and function of TAMs, and drugs that block the signaling pathways involved in MDSC recruitment and activation. Early-phase studies have shown encouraging results, but more research is needed to fully understand the therapeutic potential of these strategies.
